Experienced in Neurotrophic Keratitis

Dr. Melissa M. Toyos

Ophthalmology
West Tennessee Eye Care, PC
6465 N Quail Hollow Rd, Suite 100, 
Memphis, TN 
Accepting New Patients
Offers Telehealth
Experienced in Neurotrophic Keratitis
West Tennessee Eye Care, PC
6465 N Quail Hollow Rd, Suite 100, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melissa Toyos is an Ophthalmologist in Memphis, Tennessee. Dr. Toyos is rated as an Experienced provider by MediFind in the treatment of Neurotrophic Keratitis. Her top areas of expertise are Dry Eye Syndrome, Conjunctivitis (Pink Eye), Interstitial Keratitis, Neurotrophic Keratitis, and Cataract Removal. Dr. Toyos is currently accepting new patients.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Neurotrophic Keratitis.

Specialties
Ophthalmology
Licenses
Ophthalmology in MS
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

WEST TENNESSEE EYE CARE, PC
6465 N Quail Hollow Rd, Suite 100, Memphis, TN 38120

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 28, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery
Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Not Applicable
View 5 Less Clinical Trials

22 Total Publications

A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults.
A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults.
Journal: Ophthalmology and therapy
Published: May 10, 2025
Similar Doctors
Advanced in Neurotrophic Keratitis
Dr. John M. Freeman
Ophthalmology
Advanced in Neurotrophic Keratitis
Dr. John M. Freeman
Ophthalmology
6485 Poplar Ave, 
Memphis, TN 
 (0.3 miles away)
901-767-3937
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Freeman is an Ophthalmologist in Memphis, Tennessee. Dr. Freeman is rated as a Distinguished provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Interstitial Keratitis, Cataract, Dry Eye Syndrome, and Neurotrophic Keratitis. Dr. Freeman is currently accepting new patients.

Experienced in Neurotrophic Keratitis
Dr. James F. Freeman
Ophthalmology
Experienced in Neurotrophic Keratitis
Dr. James F. Freeman
Ophthalmology

Memphis Eye And Cataract Associates Plc

6485 Poplar Ave, 
Memphis, TN 
 (0.3 miles away)
901-767-3993
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Freeman is an Ophthalmologist in Memphis, Tennessee. Dr. Freeman is rated as an Advanced provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Interstitial Keratitis, Cataract, Dry Eye Syndrome, and Glaucoma. Dr. Freeman is currently accepting new patients.

Experienced in Neurotrophic Keratitis
Dr. Andrew W. Crothers
Ophthalmology
Experienced in Neurotrophic Keratitis
Dr. Andrew W. Crothers
Ophthalmology

Vrf Eye Specialty Group, Plc

825 Ridge Lake Blvd, 
Memphis, TN 
 (1.2 miles away)
901-685-2200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Crothers is an Ophthalmologist in Memphis, Tennessee. Dr. Crothers is rated as an Advanced provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Cataract, Interstitial Keratitis, Pterygium, and Neurotrophic Keratitis. Dr. Crothers is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Toyos's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile